Supported by the improved availability of vaccines and relatively efficient national immunisation programmes, 2022 is expected to be the year of normalisation as Asean countries shift their focus to economic reopenings.
Against this backdrop, investors need to remain vigilant on Covid-19 developments, say analysts at RHB Group Research. In an Oct 22 note, the analysts highlight that investors have grossly underestimated the impact, duration and resilience of the virus, especially in its ability to mutate into more deadly variants.
See: Standard Chartered survey reveals Singapore as top destination for Asean companies looking for growth
For more insights on corporate trends...
Sign In or Create an account to access our premium content.
Subscription Entitlements:
Less than $9 per month
Unlimited access to latest and premium articles
3 Simultaneous logins across all devices
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)
